PPSV23

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AsthmaChronic Lymphocytic LeukemiaImmunodeficiency

1050 competitors in Asthma

#DrugCompanyPhaseTrials

1

PPSV23

Merck & Co.

Approved

12

Veramyst

GSK

Preclinical

463

Xolair

Roche

Preclinical

254

Singulair

AstraZeneca

Preclinical

175

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

356

Cinqair

Teva

Preclinical

137

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

308

Asmanex

Novartis

Preclinical

59

Celexa

AbbVie

Preclinical

110

Spiriva

Boehringer Ingelheim

Preclinical

8Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity8 trials

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)

Completed·Merck & Co.·Phase 3·NCT05569954·1,484 enrolled

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

Completed·Pfizer·Phase 3·NCT04875533·1,425 enrolled

Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

Completed·Pfizer·Phase 3·NCT03760146·3,902 enrolled

Show 5 more trials

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Completed·Merck & Co.·Phase 3·NCT05420961·717 enrolled

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

Completed·Pfizer·Phase 3·NCT03835975·875 enrolled

Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)

Completed·Merck & Co.·Phase 3·NCT05633992·450 enrolled

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

Completed·Pfizer·Phase 2·NCT03313037·444 enrolled

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Completed·Merck & Co.·Phase 3·NCT05464420·2,162 enrolled

Single Ascending Dose2 trials

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

Completed·GSK·Phase 1/2·NCT03803202·630 enrolled

Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female Subjects

Completed·AAffinivax, Inc.·Phase 1·NCT04265911·126 enrolled

Phase II Clinical Trial1 trial

Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

Active, not recruiting·SShanghai Reinovax Biologics Co.,LTD·Phase 2·NCT06678620·992 enrolled

Children1 trial

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)

Completed·Merck & Co.·Phase 3·NCT06177912·882 enrolled

Clinical Trial1 trial

Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older

Completed·SShanghai Reinovax Biologics Co.,LTD·Phase 1·NCT06678607·240 enrolled

5 more indications

Asthma1 trial

Pneumococcal Vaccines in Patients With Asthma

Completed·MMayo Clinic·Phase 4·NCT03260790·17 enrolled

Vaccine Response1 trial

A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

Completed·Johnson & Johnson·Phase 1·NCT05827874·32 enrolled

Immunodeficiency1 trial

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

Completed·Merck & Co.·Phase 3·NCT05393037·313 enrolled

Pneumococcal Disease1 trial

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Completed·Merck & Co.·Phase 3·NCT05696080·518 enrolled

Chronic Lymphocytic Leukemia1 trial

Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia

Completed·RRegion Örebro County·Phase 4·NCT05316831·77 enrolled

Details

Drug Info

Related News